BCR-ABL tyrosine kinase inhibitors

A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

BCR-ABL tyrosine kinase inhibitors inhibit the enzyme BCR-ABL tyrosine kinase, which is important in the pathogenesis of chronic myelogenous leukemia (CML).

Chronic myelogenous leukemia occurs due a single genetic abnormality, known as the Philadelphia chromosome. During the translocation when the Philadelphia chromosome is created, a fusion gene called BCR-ABL gene is formed. The BCR-ABL gene encodes for the BCR-ABL tyrosine kinase. The BCR-ABL positive cells in chronic myelogenous leukemia have increased proliferation and resistance to cell death.

BCR-ABL tyrosine kinase inhibitors are used to treat chronic myelogenous leukemia.

Filter by:
Drug Name DownUp( View by: Brand | Generic ) Reviews Ratings DownUp
dasatinib systemic (Pro, More...)
8 reviews
Rate it
imatinib systemic (Pro, More...)
26 reviews
Rate it
nilotinib systemic (Pro, More...)
20 reviews
Rate it
ponatinib systemic (Pro, More...)
1 review
Rate it
bosutinib systemic (Pro, More...)
0 reviews
Rate it